(GETI-B) Getinge ser. - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000202624
GETI-B: Medical, Equipment, Ventilators, Monitors, Sterilizers, Solutions
Getinge AB (publ), a Swedish-based company founded in 1904 and headquartered in Gothenburg, is a leading provider of medical equipment and solutions tailored for critical care environments and life science research. The company operates through three distinct segments: Acute Care Therapies, Life Science, and Surgical Workflows, each addressing specific needs within healthcare.
The Acute Care Therapies segment offers advanced life-support solutions, including extracorporeal membrane oxygenation (ECMO) and mechanical ventilation, crucial for intensive care units. This segment also provides mechanical circulatory support systems and advanced patient monitoring tools, essential for critical care environments.
The Life Science division focuses on solutions for biopharmaceutical and biotechnological applications, such as bioreactor systems and isolators, aiding in the production of pharmaceuticals. Additionally, this segment provides equipment for handling biohazardous materials and sterilization processes, enhancing research and production efficiency.
The Surgical Workflows segment delivers integrated operating room solutions, including anesthesia machines and surgical lighting. This segment also offers tools for patient flow management and advanced monitoring systems, optimizing surgical procedures and post-operative care.
With a strong global presence, Getinge distributes its products through a network of sales companies, agents, and distributors across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. This extensive reach underscores the companys scalability and market penetration.
Key financial metrics for investors include a market capitalization of 59,649.03M SEK, a P/E ratio of 36.50, and a forward P/E of 17.67, indicating potential growth. The P/B ratio of 1.81 and P/S ratio of 1.78 provide further insight into the companys valuation relative to its assets and revenue.
For more detailed information, investors can visit the companys website at https://www.getinge.com.
Additional Sources for GETI-B Stock
GETI-B Stock Overview
| Market Cap in USD | 5,424m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception |
GETI-B Stock Ratings
| Growth 5y | 10.6% |
| Fundamental | 36.1% |
| Dividend | 70.7% |
| Rel. Strength Industry | 5.2 |
| Analysts | - |
| Fair Price Momentum | 210.33 SEK |
| Fair Price DCF | 297.12 SEK |
GETI-B Dividends
| Dividend Yield 12m | 4.29% |
| Yield on Cost 5y | 5.77% |
| Annual Growth 5y | 7.96% |
| Payout Consistency | 94.3% |
GETI-B Growth Ratios
| Growth Correlation 3m | 95.1% |
| Growth Correlation 12m | -15% |
| Growth Correlation 5y | 3.7% |
| CAGR 5y | 7.06% |
| CAGR/Max DD 5y | 0.12 |
| Sharpe Ratio 12m | 0.26 |
| Alpha | 2.53 |
| Beta | 0.05 |
| Volatility | 32.67% |
| Current Volume | 2786.5k |
| Average Volume 20d | 420.6k |
As of February 22, 2025, the stock is trading at SEK 219.80 with a total of 2,786,464 shares traded.
Over the past week, the price has changed by +3.61%, over one month by +11.74%, over three months by +32.93% and over the past year by +7.59%.
Partly, yes. Based on ValueRay Fundamental Analyses, Getinge ser. (ST:GETI-B) is currently (February 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 36.09 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GETI-B as of February 2025 is 210.33. This means that GETI-B is currently overvalued and has a potential downside of -4.31%.
Getinge ser. has no consensus analysts rating.
According to ValueRays Forecast Model, GETI-B Getinge ser. will be worth about 228.8 in February 2026. The stock is currently trading at 219.80. This means that the stock has a potential upside of +4.08%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 240.7 | 9.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 228.8 | 4.1% |